Slide 1: Evotec Fourth Quarter and Full-Year 2025 Results
Evotec Fourth Quarter and Full-Year 2025 Results Foundation for Profitable Growth April 8, 2026
Slide 2: Today’s Speakers
Today’s Speakers Christian Wojczewski Business Update CEO Paul Hitchin Financial Update CFO Cord Dohrmann Q&A Availability CSO PAGE 2
Slide 3: Disclaimer
Disclaimer Cautionary Note Regarding Forward-Looking Statements This presentation (including any information which has been or may be supplied This presentation contains forward-looking statements concerning our business, in writing or orally in connection here with or in connection with any further
Slide 4: Highlights: Solid Delivery and Strategic Progress
Highlights: Solid Delivery and Strategic Progress A foundation for sustainable growth D&PD Just – Evotec Biologics FY 2025 Group Reporting Pipeline Progress Breakthrough Year Group revenues: €788.4 m, €810.4 m CER (Guidance €760-800 m) Advancement of multiple assets Strong growth supported by enteri
Slide 5: D&PD: Translating Discovery into Clinical Impact
D&PD: Translating Discovery into Clinical Impact Continued progression of partnered high-value assets from discovery into clinical development Major clinical progress across key alliances Robust momentum in long- • BMS – Protein Degradation: standing partnerships First molecular glue degrader from I
Slide 6: Just – Evotec Biologics: Scaling Technology-Driven Growth
Just – Evotec Biologics: Scaling Technology-Driven Growth Advancing a scalable, capital-efficient model and expanding high-value global health programs Driving impact in public health programs Strategic shift toward scalable • BARDA – Antibody Biomanufacturing: technology-licensing model Optimizatio
Slide 7: Condensed Income Statement Full-Year 2025
Condensed Income Statement Full-Year 2025 Strong growth in JEB while facing persistent softness in early discovery Three month ended Dec 31, Twelve month ended Dec 31, in € m1 2025 2024 Change 2025 2024 Change External Revenues 253.3 221.2 14.5% 788.4 797.0 -1.1% D&PD 137.1 164.4 -16.6% 528.9 611.4
Slide 8: Quarterly Liquidity Development
Quarterly Liquidity Development Strengthened balance sheet and net cash position at year-end 2025 Net debt (net cash) 43 107 114 246 (40) in € million Monetizing technology leadership 1 through JEB Realizing value from equity 2 stakes as portfolios mature 476 397 Advancing a CAPEX-lighter, more Liqu
Slide 9: BMS Collaboration: Advancing Next-Generation of Protein Degraders
BMS Collaboration: Advancing Next-Generation of Protein Degraders A structured evolution from platform investment to emerging clinical opportunities in oncology ~2018 - 2021 ~2022 - 2024 ~2024 - 2026 ~2027 - onward T RVES HARVEST HAVEST Expansion Realization NVEST IINV INVEST Foundation Maturation B
Slide 10: EVOequity: Phasing From Investment to Asset Monetization
EVOequity: Phasing From Investment to Asset Monetization From portfolio build up to value realization Investment Monetization Inception Phase Collaboration Phase Divestment Phase 2016-2022 2018-today 2024-onward Creating portfolio of ~40 early-stage Scientific co-creation, leveraging Monetizing valu
Slide 11: Horizon: Transforming Evotec for Sustainable Growth
Horizon: Transforming Evotec for Sustainable Growth Multi-stage transition from stabilization to intensified value creation 2026 2027 Reduce global footprint from Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 currently 14 sites to 10 Reduce workforce by approx. Operational 800 positions Workers Site closures* Council Exc
Slide 12: New Chief Commercial Officer: Strengthening Commercial Execution
New Chief Commercial Officer: Strengthening Commercial Execution Driving stronger commercial impact, execution and customer engagement across global footprint Dr. Ashiq H. Khan • >15 years of global dealmaking and commercial Mandate & Priorities leadership across biotech, CRO and AI-driven discovery
Slide 13: Commercial Momentum Across Leading Indicators
Commercial Momentum Across Leading Indicators Improving funnel activity in Discovery and showing potential stabilization trend Strategic partnership Net sales oder funnel Proposal turn- progression Negative change Number and around time orders value of proposals PAGE 13
Slide 14: Full-year 2026 Revenue Outlook Driven By Segment Dynamics
Full-year 2026 Revenue Outlook Driven By Segment Dynamics Second half strengthening on segment growth and strategic contributions 371.2 Soft market impacting H1 2026 revenue • 2026 expansion of non-Sandoz H1 JEB customer value expected to Group Revenues more than offset reduced DoW €700-780 m revenu
Slide 15: Enabling Sustainable Growth by 2030
Enabling Sustainable Growth by 2030 2026-2030 medium-term framework aligned with Horizon transformation roadmap EBITDA margin 20% >20% Revenue CAGR >€1 bn (8-12% CAGR) PAGE 15
Slide 16: Roadmap to Sustainable Medium-Term EBITDA Expansion
Roadmap to Sustainable Medium-Term EBITDA Expansion Structural efficiencies and business growth driving margin improvement toward >20% by 2030 >20% • Customer base Horizon run rate cost savings • New products €75 million ~20% • Royalties • Customer base • New products • BMS collab. • Revenue growth
Slide 17: New Chairman of the Supervisory Board: Strengthening Governance
New Chairman of the Supervisory Board: Strengthening Governance Supporting strategic oversight to support Evotec’s transformation and value creation Dieter Weinand • Industry veteran with >30 years of global pharmaceutical leadership experience Mandate & Priorities • Former member of Board of Manage
Slide 18: Key Messages
Key Messages Disciplined delivery, transformation in motion, and a clear path to sustainable value creation 1 Strong 2025 financial delivery at the high end of guidance, demonstrating disciplined execution, cost and CAPEX control 2 Clear and actionable pathway to sustainable, profitable growth throu
Slide 19: Thank you
Thank you Dr. Sarah Fakih EVP Head of Global Communications & Investor Relations +49 (0) 151 7068 8784 (m) sarah.fakih@evotec.com